Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/76098
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | "Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again? |
Author: | Price, T. Townsend, A. Beeke, C. Bishnoi, S. Padbury, R. Maddern, G. Karapetis, C. |
Citation: | Asia Pacific Journal of Clinical Oncology, 2012; 8(1):10-13 |
Publisher: | Blackwell Publishing Ltd. |
Issue Date: | 2012 |
ISSN: | 1743-7555 1743-7563 |
Statement of Responsibility: | Timothy J. Price, Amanda R. Townsend, Carol Beeke, Sarwan Bishnoi, Robert Padbury, Guy Maddern and Christos S. Karapetis |
Abstract: | AIM: The role of chemotherapy in metastatic colorectal cancer (mCRC) is firmly established and the option of watchful waiting (WW) has become an alternative rarely considered. However, there may be a group of patients who are diagnosed with low volume and asymptomatic disease and who may be suitable for a WW plan. METHODS: From the South Australian Cancer Registry for mCRC we examined cancer characteristics and outcomes of patients who were suitable for chemotherapy but had their treatment delayed by more than 3 months from diagnosis of metastatic disease. RESULTS: Data from 417 mCRC patients who received chemotherapy as first intervention have been entered in the Registry to date and 38 (9.1%) had chemotherapy commencement delayed by more than 3 months from diagnosis. Their median age was 76.7 years (range 38–85). Overall 87% of patients had metachronous metastatic cancer with a median time to recurrence of 2.1 years (range 0.53–7.71) and 65.5% had single organ metastasis. Median delay from the diagnosis of metastatic disease to chemotherapy was 5.03 months (range 3–28). The median survival has yet to be reached. The 2-year overall survival is 65%. CONCLUSION: We found that almost 10% of all patients with mCRC had a delay in the initiation of chemotherapy, with most due to a WW approach based on case note review. Patients with a delay in chemotherapy initiation are more likely to have a single organ site of metastatic disease and are older than those who do not. Despite the treatment delay, there is no evidence of a negative impact on survival. |
Keywords: | Chemotherapy colorectal survival watchful waiting |
Rights: | © 2012 Blackwell Publishing Asia Pty Ltd. |
DOI: | 10.1111/j.1743-7563.2011.01458.x |
Published version: | http://dx.doi.org/10.1111/j.1743-7563.2011.01458.x |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.